Genetic variation at the CYP2C locus and its association with torsemide biotransformation

被引:18
作者
Vormfelde, S. V. [1 ]
Schirmer, M.
Toliat, M. R.
Meineke, I.
Kirchheiner, J.
Nuernberg, P.
Brockmoeller, J.
机构
[1] Univ Gottingen, Med Ctr, Dept Clin Pharmacol, D-37075 Gottingen, Germany
[2] Univ Cologne, Cologne Ctr Genom, Cologne, Germany
[3] Univ Cologne, Inst Genet, D-5000 Cologne, Germany
[4] Univ Ulm, Dept Pharmacol Nat Prod & Clin Pharmacol, Ulm, Germany
关键词
CYP2C9; evolutionary selection; haplotype; hepatic clearance; polymorphism; torsemide; HEPATIC CYTOCHROME-P450 2C9; HAPLOTYPE-BLOCK STRUCTURE; HUMAN DRUG-METABOLISM; FUNCTIONAL-CHARACTERIZATION; 5'-FLANKING REGION; HEALTHY-VOLUNTEERS; S-WARFARIN; POLYMORPHISMS; SELECTION; PHARMACOKINETICS;
D O I
10.1038/sj.tpj.6500410
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
In 97 unselected volunteers and two additional homozygous carriers of CYP2C9*3, we investigated the oral clearance of torsemide in relation to 37 polymorphisms at the CYP2C gene locus. Torsemide total oral clearance was linearly associated with the number of CYP2C9*3 alleles (geometric mean: 59, 40 and 20 ml/min in carriers of no, one and two alleles) and so were the methyl- and ring-hydroxylation but not the carboxylation clearance. Haplotypes including the CYP2C9*3 allele were similarly associated with the clearances but no other variant and no haplotype not including the CYP2C9*3 variant. The extended haplotype length (EHL) of the CYP2C9 haplotypes was positively associated with higher activity of the gene product. Torsemide total oral clearance was predictable with r(2) = 82.1% using plasma concentrations at 0.5, 1, 2 and 24 h. In conclusion, torsemide's biotransformation strongly depended on the CYP2C9*3 variant but no other. Higher clearance CYP2C9 haplotypes appear to be evolutionarily selected.
引用
收藏
页码:200 / 211
页数:12
相关论文
共 50 条
[1]   A single-nucleotide polymorphism tagging set for human drug metabolism and transport [J].
Ahmadi, KR ;
Weale, ME ;
Xue, ZYY ;
Soranzo, N ;
Yarnall, DP ;
Briley, JD ;
Maruyama, Y ;
Kobayashi, M ;
Wood, NW ;
Spurr, NK ;
Burns, DK ;
Roses, AD ;
Saunders, AM ;
Goldstein, DB .
NATURE GENETICS, 2005, 37 (01) :84-89
[2]   Haploview: analysis and visualization of LD and haplotype maps [J].
Barrett, JC ;
Fry, B ;
Maller, J ;
Daly, MJ .
BIOINFORMATICS, 2005, 21 (02) :263-265
[3]  
CASCORBI I, 1995, AM J HUM GENET, V57, P581
[4]   Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam [J].
Chaobal, HN ;
Kharasch, ED .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (05) :529-539
[5]   The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase [J].
Crespi, CL ;
Miller, VP .
PHARMACOGENETICS, 1997, 7 (03) :203-210
[6]   Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians [J].
DeLozier, TC ;
Lee, SC ;
Coulter, SJ ;
Goh, BC ;
Goldstein, JA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :1085-1090
[7]   CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products [J].
DeLozier, TC ;
Tsao, CC ;
Coulter, SJ ;
Foley, J ;
Bradbury, JA ;
Zeldin, DC ;
Goldstein, JA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (03) :845-854
[8]  
DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
[9]   Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin [J].
Depré, M ;
Van Hecken, A ;
Oeyen, M ;
De Lepeleire, I ;
Laethem, T ;
Rothenberg, P ;
Petty, KJ ;
Majumdar, A ;
Crumley, T ;
Panebianco, D ;
Bergman, A ;
de Hoon, JN .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (5-6) :341-346
[10]   The effect of haplotype-block definitions on inference of haplotype-block structure and htSNPs selection [J].
Ding, KY ;
Zhou, K ;
Zhang, J ;
Knight, J ;
Zhang, XG ;
Shen, Y .
MOLECULAR BIOLOGY AND EVOLUTION, 2005, 22 (01) :148-159